MMSI — Merit Medical Systems, Inc.

Summary of Merit Medical Systems (MMSI) Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $418.8 million, up 10% year-over-year (9% on a constant currency basis), exceeding guidance.
• Organic Growth: 9% driven by strong performance in both Foundational (6% growth) and Therapeutic (14% growth) product categories.
• Non-GAAP Operating Margin: Increased by 142 basis points to 22.6%.
• Non-GAAP EPS: Rose 18% year-over-year to $1.10, exceeding guidance by $0.09.
• Free Cash Flow: Generated nearly $52 million in Q2.
• Cash and Cash Equivalents: $448.7 million with total debt obligations at $747.5 million, resulting in a net leverage ratio of 1.6x.

2. Strategic Updates and Business Highlights

• Acquisitions: Integration of View Point Medical and Biolife is progressing well, with revenue contributions exceeding expectations. The OneMark detection imaging system is set to enhance the oncology product portfolio.
• Product Launches: Successful launches of SCOUT MD and the OneMark system, with positive market reception.
• New Board Member: Scott Ward elected to the Board, bringing extensive medical device industry experience.
• Strategic Planning: Ongoing development of a strategic plan for 2027-2029, focusing on growth drivers and organizational structure.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Updated to a growth range of 7.6% to 8.4% year-over-year, with organic constant currency growth projected at 6.9% to 7.5%.
• Non-GAAP EPS Guidance: Revised to $4.25 to $4.35, reflecting an 11% to 14% increase from previous guidance.
• Q3 2026 Guidance: Expected total revenue of $408 million to $413 million, representing 6% to 8% growth year-over-year.

4. Bad News, Challenges, or Points of Concern

• Tariff Impact: Continued uncertainty regarding tariffs, which could affect future margins and profitability.
• Seasonality: Anticipated seasonal decline in Q3 revenue, historically a softer quarter for the company.
• OEM Business Volatility: While Q2 saw a 15% growth in OEM sales, the business remains inherently lumpy and subject to fluctuations.

5. Notable Q&A Insights

• Procedure Volumes: No current slowdown in procedure volumes despite changes in ACA subsidies; field reports remain positive.
• OEM Growth Sustainability: Growth in the OEM segment is expected to stabilize in the mid to high single-digit range, but remains subject to quarterly fluctuations.
• Pricing Sensitivity: Competitive pricing strategies are in place for WRAPSODY in outpatient settings, with ongoing monitoring of market dynamics.
• Endoscopy Business: Positive developments in the endoscopy segment, with strong clinical evidence supporting product offerings and integration efforts.

Overall, Merit Medical Systems reported a strong Q2 2026, with significant revenue growth and improved profitability metrics, while also navigating challenges related to tariffs and seasonal fluctuations. The company remains focused on strategic initiatives and integration of recent acquisitions to drive future growth.